Emerging TROP-2 Directed ADCs Show Promise in Advanced NSCLC

Benjamin Philip Levy, MD, discusses the current landscape of emerging antibody-drug conjugates (ADCs) and their early activity in advanced lung cancer, the potential utility of oncogene-directed ADCs for patients with driver mutations, and more.

Related Keywords

Johns Hopkins University ,Maryland ,United States ,New York , ,Johns Hopkins University School Of Medicine ,Benjamin Philip Levy ,Johns Hopkins University School ,Medical Oncology ,Johns Hopkins Sidney Kimmel Cancer Center ,Sibley Memorial Hospital ,Annual New York Lung Cancers Symposium ,International Associated ,Lung Cancer ,World Lung Cancer ,Lung Cancer Conference ,News ,Antibody Drug Conjugates ,Datopotamab Deruxtecan ,Sacituzumab Govitecan ,T Dxd ,